

# Thigh muscle mass is associated with circulating valeric acid in healthy male 1

## volunteers 2

### Running title: 4

### Muscle mass and circulating valeric acid in males 5

Eva M. Hassler<sup>1</sup>, Gernot Reishofer<sup>2,5</sup>, Harald Köfeler<sup>3</sup>, Wilfried Renner<sup>4</sup>, Hannes Deutschmann H<sup>1</sup>,  
Harald Mangge<sup>4,5</sup>, Markus Herrmann<sup>4</sup>, Stefan L. Leber<sup>1</sup>, Felix Gunzer<sup>1</sup>, Gunter Almer<sup>4</sup> 8

<sup>1</sup> Division of Neuroradiology, Vascular and Interventional Radiology; Department of Radiology 10

Medical University Graz, 8036 Graz, Austria 11

<sup>2</sup> Department of Radiology, Medical University Graz, 8036 Graz, Austria 12

<sup>3</sup> Core Facility Mass Spectrometry, Center for Medical Research, Medical University Graz, 8036 Graz, 13  
Austria 14

<sup>4</sup> Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, 8036 Graz, 15  
Austria 16

<sup>5</sup> BiotechMed Graz, 8010 Graz, Austria 17

### Corresponding Author: 19

Gunter Almer 20

Clinical Institute of Medical and Chemical Laboratory Diagnostics, 21

Medical University Graz, Auenbruggerplatz, A-8036 Graz 22

Email: [gunter.almer@medunigraz.at](mailto:gunter.almer@medunigraz.at) 23

Submission includes supplementary material. 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 28

<b>Abstract:</b>	29	
Short-chain fatty acids (SCFAs) are circulating metabolites generated by gut microbiota. Recently, a link between age-related muscle loss and gut microbiota has been described, and SCFAs could play a mediating role in this relationship. Acetic, propionic, and butyric acid are the abundant forms and are considered to have health benefits, less is known about valeric and caproic acid.	30 31 32 33	
In a cross-sectional study including 155 healthy volunteers, we investigated the relationship between muscle area, as well as intramuscular adipose tissue measured by magnet resonance imaging and circulating SCFAs. SCFAs and additional parameters were measured from serum and sport activities recorded by means of a questionnaire.	34 35 36 37	
We found a significant positive association between valeric acid (VA) levels and the thigh cross-sectional muscle area in males. This relationship was independent of age, BMI and weekly training times and was not observed in females. No associations between other SCFAs and the thigh muscle cross-sectional area were observed.	38 39 40 41	
To our knowledge, this is the first human study demonstrating a significant relationship between thigh muscle mass and VA, supporting the thesis of the “gut–muscle axis“ with VA as a possible interacting player, on the one hand, affected by sex differences, on the other.	42 43 44	
	45	
<b>Word count: 4115</b>	46	
<b>Keywords:</b> Valeric acid, short-chain fatty acids, magnet resonance imaging, muscle mass	47	
<b>Abbreviations:</b>	48	
<b>CA</b>	<b>caproic acid (C6)</b>	49
<b>FFA</b>	<b>free fatty acids</b>	50
<b>GC-EI/MS</b>	<b>gas chromatograph-electron impact-mass spectrometer</b>	51

<b>IMAT</b>	<b>intramuscular adipose tissue</b>	52
<b>MA</b>	<b>muscle area</b>	53
<b>MRI</b>	<b>magnet resonance imaging</b>	54
<b>MTBE</b>	<b>methyl tert-butyl ether</b>	55
<b>SCFA</b>	<b>short-chain fatty acids</b>	56
<b>SMA</b>	<b>spinal muscular atrophy</b>	57
<b>SMN</b>	<b>survival motoneuron</b>	58
<b>VA</b>	<b>valeric acid (C5)</b>	59

60

## Introduction

61

A balanced diet and regular exercise are the cornerstones of a healthy lifestyle and still the best protection against numerous diseases on a worldwide rise, such as cardiovascular (e.g. strokes and heart attacks) or metabolic diseases (e.g. type 2 diabetes) (1, 2). In recent years, clinicians have also recognized the importance of the gut microbiome as a metabolic key player, as well as its close relationship with obesity and related cardiometabolic disorders, specifically when the microbiome is out of balance (3, 4).

One of the main groups of metabolites produced by the gut microbiome are short-chain fatty acids (SCFAs). The main origin of all SCFAs is the gut, where they are produced in the large intestine by colon microbiota fermenting indigestible food components such as fibers like complex carbohydrates and resistant starch (5, 6). They are later metabolized in colonic epithelial cells, liver and other tissues, to serve as an energy source for the body, including the muscles (7). The three most common SCFAs are acetate, propionate, and butyrate (8). All three were found to have diverse physiological functions, for instance, affecting the blood lipid profiles, vitamin concentrations and energy production (9) as well as appetite, cardiometabolic health maintenance (10) and insulin sensitivity (11). Therefore, they are not only important for intestinal health (12), but because they enter the systemic circulation, they affect metabolism and peripheral tissue functions. Furthermore, they can alter dendritic cell and macrophage function to reduce the production of pro-inflammatory cytokines and they are also involved in the regulation of glycemic responses and triglyceride metabolism (6, 7).

SCFAs are very soluble and are absorbed easily from the intestinal lumen into the blood circulation via the portal vein. Acetic acid is usually the major short-chain fatty acid in human blood circulation and was found to be a possible energy source for the liver (13, 14). Butyric acid was found to be particularly of benefit for colon health as primal energy source for colonocytes (12). A very recent work by Lv et al. showed an impact of serum levels from gut microbiota generated butyrate on the muscle mass index in healthy menopausal women (15). Furthermore, there are studies which demonstrate that

SCFAs directly influence muscle mass *in vivo* (16-18). For example, Gao et al. demonstrated that chronic 86  
supplementation with butyrate preserves skeletal muscle in relation to the total body fat mass in 87  
rodents when incorporated into a high-fat diet (17). Also, Lahiri et al. clearly demonstrated the 88  
influence of gut microbiota on gene expression in muscle tissue and transcription of genes associated 89  
with skeletal muscle growth and function in mice (18). 90

All SCFAs show age related changes (19), but compared to “the big 3” – acetic (C2), propionic (C3) and 91  
butyric acid (C4) – valeric (C5) and caproic acid (C6) are commonly present at lower concentrations in 92  
feces and the circulation, and have not been considered as SCFAs strictly produced by the microbiota 93  
until now (19). However, in a recent article, they were found to be potent class I histone acetylase 94  
inhibitors (20). Valeric acid (VA) was further shown to inhibit the growth of *Clostridium difficile* when 95  
it was restored by fecal microbiota transplantation (21). In another preclinical study in mice, VA was 96  
found to reduce toxic injuries that were caused by radiation (22). However, compared to the other 97  
SCFAs, very little is known about the effects of VA on intestinal health and on health in general. 98

Some studies have shown that there is a link between the microbiome and age-related muscle loss, 99  
known as the “gut–muscle axis” (23-25). It is known that the pathophysiology of age-related muscle 100  
loss could be influenced by gut microbiota through different mechanisms of chronic inflammation and 101  
anabolic resistance (26). Loss of muscle mass e.g. with ageing or inactivity could lead to an increased 102  
fatty infiltration of the muscle tissue and therefore to an increased amount of intramuscular adipose 103  
tissue (IMAT) (27, 28). IMAT is also associated with a loss of muscle function (27). Furthermore, a 104  
negative effect of the amount of IMAT on glucose metabolism has been shown and several authors 105  
found relations between IMAT in the thigh muscles and different factors of cardiometabolic risk (29- 106  
32). Moreover, it was suggested by Goodpaster et. al. that too much IMAT may lead to an elevated 107  
free fatty acid (FFA) concentration in the skeletal muscles, which could cause a reduction in 108  
intramuscular blood flow followed by lower insulin diffusion capacity (33). 109

To achieve an accurate and radiation-free quantification of muscle mass and IMAT, magnet resonance imaging (MRI) is the most suitable method (29, 34, 35). Due to the development of new scanning techniques, examinations can nowadays be carried out in reasonable time (36, 37).

In the present study, we investigated a possible relationship between SCFAs, muscle mass and intramuscular adipose tissue in our study cohort of healthy active volunteers. Since other studies have shown associations between the gut microbiome and age-related muscle loss in men (24), we further wanted to investigate sex differences as well as relationships with body composition. Additionally, we compared the measured parameters between information on endurance and strength training.

118

## Materials and Methods

### Subjects.

The included study subjects all gave written informed consent. The study participants were recruited from 12th of April 2018 until the 2nd February of 2019, and the study was approved by the local Ethics Committee of the Medical University Graz; (approval number: EK-Nr. 29-585 ex 16/17). The study had a cross-sectional design and 155 volunteers (78 females and 77 males) were included in the study. Some of the samples and data from our MRI-adipose tissue measurement study have been used and already published (38, 39). We excluded volunteers with known hyperlipidemia, metabolic disorders such as diabetes, and neurological and muscle diseases. Additionally, metallic implants and/or claustrophobia were reasons for study exclusion to MRI examinations. We collected parameters such as the height, weight, waist and hip circumference in every volunteer. We calculated ratios such as the waist/hip ratio and waist/height ratio.

The participants were given a questionnaire to note frequency, duration and nature of their sport activities as well as their lifestyle and dietary style (see supplements S1). The training frequency and

duration were divided according to different training modes, in both endurance and resistance 134  
training. At the time of study inclusion, all subjects were healthy, and no one reported taking any 135  
antibiotics. 136

137

### **Magnetic resonance imaging (MRI) and image processing**

138

We performed MRI examination of the thigh after standardized positioning of a marker using a 3 Tesla 139  
magnetic resonance scanner (Siemens MAGNETOM® Prisma, Siemens Healthcare, Erlangen, 140  
Germany). The marker enables an exact localization of the measurements by using a standardized 141  
method developed by Mueller et al. (40). The MRI protocol consists of a standard 2-Point DIXON 142  
Sequence (TR 4.66ms, TE1 1.24ms, TE2 2.47ms, Flip angle 9°, base resolution 288, ISO Voxel Size: 1.4 x 143  
1.4x1.4mm, PAT 4). 144

MRI data were analyzed using FIJI, which is an open-source image-processing package based on 145  
ImageJ (41). We used the image slice with the visible marker position for quantitative segmentation. 146  
The cross-sectional muscle area (MA) and intramuscular adipose tissue (IMAT) compartment were 147  
evaluated separately. The MA and percentage of IMAT in between the MA were calculated (38). Figure 148  
1 shows segmentation results for and muscle area. 149

150

### **Blood collection and clinical laboratory analysis**

151

Venous blood samples were collected from every subject prior to MRI measurements. The blood 152  
samples were collected after a 12 h fasting period. Serum lipid panel contained total blood cholesterol 153  
(mg/dL), HDL (mg/dL), LDL (mg/dL), and serum triglycerides (mg/dL). The total cholesterol/HDL 154  
quotient was calculated. Serum levels of leptin (ng/ml) were analyzed using an appropriate human 155  
ELISA Kit® (BioVendor, Czech Republic) according to the manufacturer's instructions. Standards, 156  
controls (high and low) and samples were measured in duplicates. The standard curves were calculated 157

using the four-parameter algorithm. All blood samples were analyzed in the same laboratory with a 158  
standardized protocol using frozen serum (– 80 °C). 159

160

### **Determination of short chain fatty acids by gas chromatograph-electron impact-mass spectrometer** 161

#### **(GC-EI/MS)** 162

Propionic acid-d6 was purchased from EQ Laboratories (Augsburg, Germany) and all other chemicals 163  
were supplied from Sigma Aldrich (St. Louis, MO, USA). A measure of 10 µl of an internal standard mix 164  
was added to 100 µl of serum samples, resulting in a final concentration of 100 µM acetic acid-d4, 165  
propionic acid-d6, butyric acid-d8, valeric acid-d9 and hexanoic acid-d3 each. Subsequently, 110 µl of 166  
methyl tert-butyl ether (MTBE) was added. The mixture was shaken for 10 min and then centrifuged 167  
in a lab centrifuge at 2500 rpm. The upper phase was transferred into a GC–MS vial. The injection 168  
volume was 1 µl in splitless mode at 250°C injector temperature. The GC oven was equipped with a 1 169  
DB-WAX UI GC-column (30m x 0.25mm ID x 0.25µm film) and an initial oven temperature of 40°C was 170  
held for 2 min. Thereafter, it was ramped up to 150°C at a rate of 15°C/ min followed by an increase of 171  
5°C/min up to 170°C and an increase of 20°C/min up to 250°C, where the temperature was finally held 172  
for 5 min. Helium was used as a carrier gas at a flow rate of 1.3 ml/min. The transfer line temperature 173  
was set to 280°C. The mass spectrometer was operated in SIM mode using the following m/z values: 174  
60, 63, 73, 74, 76, 79 and 80 at their respective retention times. Acetic (C2), propionic (C3), butyric 175  
(C4), valeric (C5) and hexanoic (C6) acid were determined by one-point calibration versus their 176  
corresponding internal standards. 177

178

#### **Statistics** 179

Statistics were performed using SPSS version 27 (IBM). Group differences between males and females 180  
in the descriptive evaluation have been performed using Welch’s *t*-test. Statistical comparison of 181



parametric continuous subject characteristics was accomplished using the two-sided Student's *t*-test 182  
with Pearson's linear correlation coefficients over the whole study population and separated into 183  
groups according to sex. The distribution was tested for normality using the Shapiro–Wilk test. A *p*- 184  
value <0.05 was considered to be statistically significant. A stepwise multiple linear regression analysis 185  
was performed to adjust the relations for age, BMI, training activities and serum lipid panel including 186  
Fisher's *z*-transformation for the Pearson correlation coefficients. 187

188

189

**Results** 190

**Subjects** 191

The study had a cross-sectional design including 155 volunteers; 78 females/77 males; age: min 21.4- 192  
 max 76.3 (males 41.65 ± 11.53/mean ± SD, females 45.31 ± 10.41/mean ± SD). Table 1 shows the age, 193  
 BMI, waist/hip and waist/height ratios, muscle areas and areas of adipose tissue compartments 194  
 including the ratios of the fat compartments, respectively, and serum levels of SCFAs, as well as the 195  
 lipid profile of the entire study population. The parameters were indicated for both males and females. 196

The BMI was statistically significantly higher in the male group than in females. The muscle cross- 197  
 sectional area showed significantly higher values in the male group than in females. The percentage of 198  
 IMAT per MA was significantly lower in the male group. HDL was higher in females. No statistically 199  
 significant differences were found between the weekly endurance training times in men and women, 200  
 but men performed significantly longer weekly resistance training units. Comparing the levels of all 201  
 SCFAs between both sexes, no significant differences were found between men and women (Table 1). 202

**Table 1:** Descriptive statistics of the study population.

Anthropometric measurements	Total (n=155)		Female (n=78)		Male (n=77)		p-value
age (years)	43.47	± 11.10	45.31	± 10.41	41.65	± 11.53	0.040*
BMI kg/m <sup>2</sup> )	23.74	± 3.12	22.88	± 3.29	24.60	± 2.70	<b>0.001***</b>
Waist/hip ratio	0.82	± 0.07	0.78	± 0.06	0.86	± 0.07	< <b>0.001***</b>
Waist/height ratio	0.47	± 0.05	0.46	± 0.06	0.48	± 0.05	<b>0.009***</b>
<b>Compartments and ratios</b>							
Muscle cross-sectional area (px)	14253.08	± 3395.47	11702.30	± 1486.93	16771.17	± 2818.97	< <b>0.001***</b>
SAT/(SAT+IMAT)	0.88	± 0.05	0.89±	± 0.05	0.87±	± 0.05	<b>0.007**</b>
IMAT/MA	0.06	± 0.05	0.08	± 0.05	0.04±	± 0.02	< <b>0.001***</b>
<b>Laboratory measurements</b>							
Leptin	8.46	± 8.73	9.15	± 9.20	7.68	± 8.18	0.312
<b>Lipid profile</b>							
Total blood cholesterol (mg/dl)	194.81	± 32.49	200.18	± 30.15	189.51	± 34.02	<b>0.040*</b>
HDL-C (mg/dl)	68.97	± 17.78	76.10	± 18.74	61.94	± 13.60	< <b>0.001***</b>
LDL-C (mg/dl)	102.93	± 30.84	102.74	± 29.37	103.10	± 32.36	0.943

Triglycerides (mg/dl)	115.56	± 88.95	108.17	± 99.68	122.86	± 76.87	0.306
<b>SCFA</b>							
C2 (μmol/L)	10700.92	± 9583.07	10207.33	± 8810.55	11188.19	± 10239.52	0.523
C3 (μmol/L)	572.33	± 353.33	566.44	± 335.27	578.13	± 372.39	0.838
C4 (μmol/L)	56.51	± 32.43	54.50	± 30.00	58.49	± 34.76	0.446
C5 (μmol/L)	11.77	± 7.83	11.07	± 7.36	12.48	± 8.06	0.257
C6 (μmol/L)	60.52	± 40.72	58.14	± 38.96	62.86	± 42.51	0.472
<b>Sport profile</b>							
Endurance (min/w)	221.20	± 371.15	188.65	± 403.77	253.33	± 335.50	0.280
Resistance (min/w)	87.00	± 105.18	67.18	± 85.88	106.56	± 118.59	<b>0.019*</b>
Endurance (Sessions/w)	2.72	± 2.12	2.59	± 2.22	2.84	± 2.01	0.455
Resistance (Sessions/w)	1.71	± 1.86	1.41	± 1.70	2.01	± 1.97	<b>0.044*</b>

*Sex differences were evaluated via t-test. The shown p-values mark significant sex differences (values are reported as mean ±SD). Intermuscular adipose tissue (IMAT); subcutaneous adipose tissue (SAT); low-density lipoprotein (LDL); high-density lipoprotein (HDL); p < .05 indicated as \*, p < .01 indicated as \*\*, p < .001 indicated as \*\*\**

203

### Pearson correlations differ in males vs. females

204

Table 2 shows the correlation of SCFAs, adipose tissue and muscle tissue segmentation results. The most interesting observation in this study was a significant correlation of the cross-sectional muscle area of the mid-thigh with circulating VA (C5) in healthy males ( $r=0.324/p\text{-value}=.004$ ). This association was not found in females ( $r=-.030/p\text{-value}=.793$ ). The scatterplots of VA versus muscle mass are shown in Fig.2. No correlation was found between circulating SCFAs and the weekly duration of resistance training in both males and females.

210

**Table 2:** Pearson correlation results between SCFA serum levels, thigh MA, intermuscular adipose tissue segmentation results, and weekly training times.

	Sex	C2	C3	C4	C5	C6
		r	r	r	r	r
Features		p.	p	p	p.	p

MA	Male	0.038	0.083	0.149	0.324	0.101
		0.77	0.47	0.19	<b>0.004**</b>	0.38
	Female	0.041	0.078	0.008	-0.030	0.108
		0.73 / 0.96	0.50 / 0.92	0.95 / 0.98	0.79 / 0.95	0.94 / 0.99
IMAT/MA	Male	-0.041	-0.025	-0.054	-0.119	0.099
		0.72 / 0.99	0.83 / 0.97	0.64 / 0.95	0.30 / 0.98	0.39 / 0.93
	Female	-0.124	-0.183	-0.183	-0.109	0.076
		0.28 / 0.99	0.11 / >0.99	0.11 / 0.97	0.35 / 0.93	0.51 / 0.91
Resistance (min w)	Male	-0.003	0.095	0.098	0.059	-0.105
		0.98 / 0.99	0.41 / 0.94	0.39 / 0.91	0.61 / 0.96	0.36 / 0.95
	Female	0.041	-0.008	-0.032	-0.031	-0.155
		0.72 / 0.97	0.95 / 0.98	0.78 / 0.98	0.79 / 0.96	0.18 / 0.77
Endurance (min w)	Male	-0.017	-0.031	0.000	0.112	0.169
		0.88 / 0.99	0.79 / 0.96	>0.99 / >0.99	0.33 / 0.95	0.14 / 0.85
	Female	-0.080	-0.035	-0.051	-0.104	-0.077
		0.49 / 0.91	0.76 / 0.99	0.66 / 0.97	0.37 / 0.92	0.51 / 0.91

*Pearson correlation coefficients  $r$ , and corresponding  $p$ -values are displayed. Intermuscular adipose tissue (IMAT), ;  $p < .05$  indicated as \*,  $p < .01$  indicated as \*\*,  $p < .001$  indicated as \*\*\**

211

212

### Results of the multivariate regression analysis

213

In an additional multivariate regression analysis with VA (C5) as constant, we could show that the

214

relationship between the cross-sectional muscle area and VA in males remains significant. The model

215

was adjusted for age, BMI, endurance and resistance training times and serum lipids. In females, none

216

of the factors are related or influenced the VA levels (Table 3. a, b).

217

**Table 3a:** Effect of cross-sectional MA, age, body mass index, resistance and endurance training and serum lipid panel on VA levels in men (stepwise inclusion).

Predictor	t-value	Pr(> t )	Fstat (p-value)
-----------	---------	----------	-----------------

	$\beta$ -coefficients		adj. R2	8.606
			0.091	(0.004**)
Constant		-0.557	0.579	
MA	<b>0.321</b>	<b>2.934</b>	<b>0.004**</b>	
Age	0.034	0.304	0.762	
BMI	-0.162	-1.296	0.199	
Endurance time/week	0.040	0.355	0.723	
Endurance units/week	0.083	0.736	0.464	
Resistance time/week	-0.056	-0.482	0.632	
Resistance units/week	0.072	0.631	0.530	
Cholesterol(mg/dl)	-0.127	-1.157	0.251	
LDL (mg/dl)	-0.090	-0.819	0.451	
HDL (mg/dl)	0.052	0.472	0.638	
Triglycerides (mg/dl)	-0.133	-1.203	0.233	

Standardized  $\beta$ - coefficients, t- values and associated p-values are shown. Dependent variable: VA (C5).

218

**Table 3b:** Effect of cross-sectional MA, age, body mass index, resistance and endurance training and serum lipid panel on VA levels in women (stepwise inclusion).

Predictor	$\beta$ -coefficients	t-value	Pr(> t )	adj. R2	Fstat (p-value)
				0.015	1.186 (0.318)
Constant		2.052	0.044		
MA	0.063	0.429	0.669		
Age	0.198	1.383	0.172		
BMI	-0.190	-1.191	0.238		
Endurance time/week	-0.018	-0.125	0.901		
Endurance units/week	-0.272	-1.899	0.062		
Resistance time/week	0.162	0.575	0.567		
Resistance units/week	-0.093	-0.351	0.727		
Cholesterol(mg/dl)	-0.102	-0.665	0.509		

HDL (mg/dl)	-0.225	-1.530	0.131
Triglycerides (mg/dl)	0.158	1.139	0.259

*Standardized  $\beta$ - coefficients, t- values and associated p-values are shown. Dependent variable: VA (C5).*

219

When the cross-sectional muscle area was used as the dependent variable in the model, again, VA was found to be a significant influencing factor along with BMI, age, weekly weight training duration, the number of weekly endurance training sessions, and HDL. Again, in the female group, there was no correlation with VA (Table 4. a, b).

220  
221  
222  
223

**Table 4a:** Effect of VA, age, body mass index, resistance and endurance training and serum lipid panel on cross-sectional muscle area in men (stepwise inclusion).

Predictor	$\beta$ -coefficients	t-value	Pr(> t )	adj. R2	Fstat (p-value)
Constant		1.833	0.069	<b>0.091</b>	<b>8.606 (0.004**)</b>
<b>BMI</b>	<b>0.472</b>	<b>7.020</b>	<b>&lt;0.001***</b>		
<b>Resistance time/week</b>	<b>0.238</b>	<b>3.860</b>	<b>&lt;0.001***</b>		
<b>Endurance units/week</b>	<b>0.237</b>	<b>3.979</b>	<b>&lt;0.001***</b>		
<b>Age</b>	<b>-0.231</b>	<b>3.759</b>	<b>&lt;0.001***</b>		
<b>C5 (VA)</b>	<b>0.150</b>	<b>2.531</b>	<b>0.012*</b>		
<b>HDL (mg/dl)</b>	<b>-0.152</b>	<b>-2.279</b>	<b>0.024*</b>		
Endurance time/week	0.102	0.137	0.706		
Resistance units/week	0.274	-0.092	0.272		
Cholesterol(mg/dl)	0.289	-0.089	0.738		
LDL (mg/dl)	0.285	-0.090	0.708		
Triglycerides (mg/dl)	0.935	-0.007	0.722		

*Standardized  $\beta$ - coefficients, t- values and associated p-values are shown. Dependent variable: MA.*

224

**Table 4b:** Effect of VA, age, body mass index, resistance and endurance training and serum lipid panel on cross-sectional muscle area in women (stepwise inclusion).

Predictor	$\beta$ -coefficients	t-value	Pr(> t )	adj. R2	Fstat (p-value)
Constant		5.818	0.044	0.260	13.438 (<0.001***)
<b>BMI</b>	<b>0.465</b>	<b>4.549</b>	<b>&lt;0.001***</b>		
<b>Resistance time/week</b>	<b>0.250</b>	<b>2.452</b>	<b>0.017**</b>		
C5 (VA)	-0.470	0.459	0.647		
Age	-0.135	-1.291	0.201		
Endurance time/week	0.117	1.067	0.294		
Endurance units/week	0.162	1.599	0.114		
Resistance units/week	-0.125	-0.585	0.560		
Cholesterol(mg/dl)	-0.145	-1.409	0.163		
HDL (mg/dl)	0.153	1.323	0.190		
LDL (mg/dl)	-0.162	-1.483	0.143		
Triglycerides (mg/dl)	-0.157	1.498	0.139		

*Standardized  $\beta$ - coefficients, t- values and associated p-values are shown. Dependent variable: MA.*

225

226

## Discussion

227

Evidence showing the metabolic effects of the physiologically lower concentrated SCFAs VA and CA is still lacking. To our knowledge, we are the first to show a significant association of the cross-sectional muscle area of the thigh with circulating VA. The second interesting observation is that it was only found in healthy males. Furthermore, the relationship remained statistically significant in a multivariate regression analysis with VA as the dependent variable adjusted for age and BMI. Neither

228

229

230

231

232

the endurance or resistance training time and units per week showed a statistically significant 233  
relationship with VA (C5) in the multivariate regression model. 234

The cause-and-effect principle of our observation cannot be clearly answered at this stage. Different 235  
underlying pathophysiological mechanisms could explain the influence of the gut microbiome on 236  
skeletal muscle metabolism (18, 23). Therefore, we assume, that VA could influence muscle mass. 237

On the other hand, muscle mass may also have an influence on serum levels of VA. Several studies 238  
showed that exercise affects muscle mass, and the microbial diversity in the gut was suggested to be 239  
increased (42-44), involving mechanisms such as myokine release, increased intestinal transit, or the 240  
secretion of neurotransmitters and hormones, including the promotion of an anti-inflammatory state 241  
(43-46). Some animal studies using mouse and rat models indicated changes in the gut microbiome 242  
with an increase in several short-chain fatty acid (SCFA)-producing bacteria in mice after strength 243  
training (47, 48). A recent study on elite athletes indicated that the gut microbiota could influence their 244  
training performance. They found that *Veillonella atypica* was positively associated with increased 245  
physical performance by the metabolization of lactate into propionate in these high-performance 246  
athletes (49). A longitudinal study in humans describes changes in the gut microbiome after completing 247  
an 8-week endurance program (50). Here, no changes were found after an 8-week intervention with 248  
strength training. 249

Compared to these studies, we did not observe a significant influence of endurance or resistance 250  
training times on VA levels in males in a multilinear regression analysis, but although we did find a 251  
significant influence of training interventions on the cross-sectional muscle area. A reason for this 252  
could be the recording of our training modalities with a questionnaire, which may be seen as a study 253  
limitation in this context. 254

Recent research with mice found an association of gut microbiota dysbiosis with an 255  
underrepresentation of species involved in SCFA synthesis and reduced expression of free fatty acid 256  
receptors in enteroendocrine cells, leading to a negative effect for the glucose metabolism of skeletal 257



muscle cells (51). Furthermore, a link between insulin sensitivity and circulating SCFAs has been 258  
described in human studies (11). In this context, studies demonstrated that the G protein-coupled 259  
receptor 41 plays a role in insulin responsiveness and is enhanced by both propionic and valeric acids 260  
on glucose uptake shown in 3T3-L1 adipocytes and C2C12 myotubes; furthermore, a valerate-induced 261  
increase in basal glucose uptake in C2C12 myotubes was found, suggesting a role for VA in muscle 262  
metabolism (52, 53). 263

Since the amount of intramuscular adipose tissue is also independently associated with insulin 264  
resistance, we would have expected a relationship between IMAT/MA and acetic or valeric acid in this 265  
context (11, 30, 31), but that was surprisingly not the case. Using the Welch's test, we did not find 266  
significant differences in the VA levels between males and females, contrary to other studies (54). 267  
Nevertheless, we found an expected difference in the cross-sectional muscle area of the thigh between 268  
males and females. 269

However, our observation supports the findings of previous studies that have shown differences in the 270  
gut microbiome between sarcopenic and non-sarcopenic male subjects (23, 24). Compared to that 271  
study, we included healthy male and active subjects. The prior study, which found a causal effect 272  
between gut microbial synthesis of SCFA butyric acid and the appendicular muscle mass in 273  
postmenopausal healthy women (15), could not be supported by our results as we did not observe this 274  
in our female cohort. Nevertheless, the associations we observed between VA and MA in males suggest 275  
that muscle mass influences VA rather than *vice versa*, as we did not see this observation in females, 276  
possibly due to the lower average muscle mass. 277

By now, only some single studies used VA for therapeutical application. One animal study showed VA 278  
glyceride ester feeding to chicken broilers. It resulted in a positive influence of aspects of their 279  
performance and a reduction in the number of necrotic enteritis incidences (55). Interestingly, valproic 280  
acid, a branched SCFA derivate of VA, is already used as a therapeutic agent for spinal muscular atrophy 281  
(SMA). Its administration led to an increase in the expression of survival motoneuron (SMN) mRNA (56, 282

57). Furthermore, treatment with valproic acid resulted in an improvement in gross motor functions 283  
for SMA patients (57). Whether the intestinally produced valproic acid can interact with SMN protein 284  
levels and thereby have effects on, e.g., muscle mass, or what underlying mechanisms could be 285  
responsible for the relationship between muscle mass and VA observed in our male cohort are not 286  
currently clear and would need further investigation to ascertain. 287

288

There are some other limitations to this study. The sex hormone status was not recorded, which could 289  
play an important role in the build-up of muscle mass. Additionally, information about dietary habits 290  
or the use of antibiotics and probiotics was not optimally surveyed. Thus, the observed 291  
interrelationships should be investigated in further longitudinal studies. Due to the original study 292  
design, the gut microbiota compositions were not examined in this cross-sectional study. Further 293  
research is planned to examine sex-specific relationships between gut microbiota, enteral and 294  
circulating SCFAs, and changes after training interventions. In terms of disadvantages with the 295  
recording of sporting activities with a questionnaire, we intend to carry out more precise examinations. 296  
Therefore, studies with performance diagnostics could also be carried out in the future. 297

298

In conclusion, we were able to indicate a significant association between VA and thigh muscle mass in 299  
healthy males, which, to our knowledge, has not been described before. In relation to our investigation 300  
and other studies, we suppose that training interventions, which effect muscle mass could influence 301  
the gut microbiome and consecutively VA concentrations. On the other hand, also an influence of VA 302  
on muscle mass is possible, as prior studies found an effect of the gut microbiome on muscle 303  
metabolism. Nevertheless, our observation establishes a new view on VA, as it possibly has a more 304  
important role in energy metabolism than known and could be examined more closely in future 305  
studies. 306

307

**Additional information:** Competing financial and non-financial interests are disclosed by all 308  
contributing authors. This research received no external funding. 309

## References 311

1. Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Manas LR, et al. Metabolic syndrome across Europe: different clusters of risk factors. *Eur J Prev Cardiol.* 2015;22(4):486-91. 312
2. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. *Obes Rev.* 2015;16(1):1-12. 314
3. Yu K, Yu CG, Yin XQ, Wang ZW, Wang XB, Wang LL, et al. Metabolites of gut microbiome are associated with glucose metabolism in non-diabetic obese adults: a Chinese monozygotic twin study. *Diabetol Metab Syndr.* 2021;13(1):106. 316
4. Saad MJ, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. *Physiology (Bethesda).* 2016;31(4):283-93. 319
5. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. *Adv Immunol.* 2014;121:91-119. 321
6. Wang Y, Leong LEX, Keating RL, Kanno T, Abell GCJ, Mobegi FM, et al. Opportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gut. *Gut Microbes.* 2019;10(3):367-81. 323
7. Higgins JA. Resistant starch: metabolic effects and potential health benefits. *J AOAC Int.* 2004;87(3):761-8. 326
8. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol.* 2006;40(3):235-43. 328
9. Byrne CS, Chambers ES, Morrison DJ, Frost G. The role of short chain fatty acids in appetite regulation and energy homeostasis. *Int J Obes (Lond).* 2015;39(9):1331-8. 330
10. Mueller NT, Zhang M, Juraschek SP, Miller ER, Appel LJ. Effects of high-fiber diets enriched with carbohydrate, protein, or unsaturated fat on circulating short chain fatty acids: results from the OmniHeart randomized trial. *Am J Clin Nutr.* 2020;111(3):545-54. 332
11. Müller M, Hernández MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. *Sci Rep.* 2019;9(1):12515. 335
12. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. *Nat Rev Endocrinol.* 2015;11(10):577-91. 338
13. Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? *Nutr Clin Pract.* 2006;21(4):351-66. 340
14. Calder PC. Fatty Acids: Metabolism. In: Caballero B, Finglas PM, Toldrá F, editors. *Encyclopedia of Food and Health.* Oxford: Academic Press; 2016. p. 632-44. 342
15. Lv WQ, Lin X, Shen H, Liu HM, Qiu X, Li BY, et al. Human gut microbiome impacts skeletal muscle mass via gut microbial synthesis of the short-chain fatty acid butyrate among healthy menopausal women. *J Cachexia Sarcopenia Muscle.* 2021. 344

16. Frampton J, Murphy KG, Frost G, Chambers ES. Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function. *Nat Metab.* 2020;2(9):840-8. 347-348
17. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes.* 2009;58(7):1509-17. 349-350
18. Lahiri S, Kim H, Garcia-Perez I, Reza MM, Martin KA, Kundu P, et al. The gut microbiota influences skeletal muscle mass and function in mice. *Sci Transl Med.* 2019;11(502). 351-352
19. Rios-Covian D, González S, Nogacka AM, Arboleña S, Salazar N, Gueimonde M, et al. An Overview on Fecal Branched Short-Chain Fatty Acids Along Human Life and as Related With Body Mass Index: Associated Dietary and Anthropometric Factors. *Frontiers in Microbiology.* 2020;11(973). 353-355
20. Yuille S, Reichardt N, Panda S, Dunbar H, Mulder IE. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. *PLoS One.* 2018;13(7):e0201073. 356-358
21. McDonald JAK, Mullish BH, Pechlivanis A, Liu Z, Brignardello J, Kao D, et al. Inhibiting Growth of *Clostridioides difficile* by Restoring Valerate, Produced by the Intestinal Microbiota. *Gastroenterology.* 2018;155(5):1495-507.e15. 359-361
22. Li Y, Dong J, Xiao H, Zhang S, Wang B, Cui M, et al. Gut commensal derived-valeric acid protects against radiation injuries. *Gut Microbes.* 2020;11(4):789-806. 362-363
23. Ticinesi A, Mancabelli L, Tagliaferri S, Nouvenne A, Milani C, Del Rio D, et al. The Gut-Muscle Axis in Older Subjects with Low Muscle Mass and Performance: A Proof of Concept Study Exploring Fecal Microbiota Composition and Function with Shotgun Metagenomics Sequencing. *Int J Mol Sci.* 2020;21(23). 364-367
24. Ticinesi A, Lauretani F, Milani C, Nouvenne A, Tana C, Del Rio D, et al. Aging Gut Microbiota at the Cross-Road between Nutrition, Physical Frailty, and Sarcopenia: Is There a Gut–Muscle Axis? *Nutrients.* 2017;9(12). 368-370
25. Ticinesi A, Lauretani F, Tana C, Nouvenne A, Ridolo E, Meschi T. Exercise and immune system as modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis. *Exerc Immunol Rev.* 2019;25:84-95. 371-373
26. Prokopicis K, Chambers E, Ni Lochlainn M, Witard OC. Mechanisms Linking the Gut-Muscle Axis With Muscle Protein Metabolism and Anabolic Resistance: Implications for Older Adults at Risk of Sarcopenia. *Front Physiol.* 2021;12:770455. 374-376
27. Addison O, Marcus RL, Lastayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. *Int J Endocrinol.* 2014;2014:309570. 377-378
28. Rowshan K, Hadley S, Pham K, Caiozzo V, Lee TQ, Gupta R. Development of fatty atrophy after neurologic and rotator cuff injuries in an animal model of rotator cuff pathology. *J Bone Joint Surg Am.* 2010;92(13):2270-8. 379-381
29. Boettcher M, Machann J, Stefan N, Thamer C, Haring HU, Claussen CD, et al. Intermuscular adipose tissue (IMAT): association with other adipose tissue compartments and insulin sensitivity. *J Magn Reson Imaging.* 2009;29(6):1340-5. 382-384
30. Gallagher D, Kuznia P, Heshka S, Albu J, Heymsfield SB, Goodpaster B, et al. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. *Am J Clin Nutr.* 2005;81(4):903-10. 385-386
31. Yim JE, Heshka S, Albu J, Heymsfield S, Kuznia P, Harris T, et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. *Int J Obes (Lond).* 2007;31(9):1400-5. 387-389

32. Bergia RE, 3rd, Kim JE, Campbell WW. Differential Relationship between Intermuscular Adipose Depots with Indices of Cardiometabolic Health. *Int J Endocrinol*. 2018;2018:2751250. 390-391
33. Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Simonsick EM, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. *Arch Intern Med*. 2005;165(7):777-83. 392-394
34. Mercuri E, Cini C, Pichiecchio A, Allsop J, Counsell S, Zolkipli Z, et al. Muscle magnetic resonance imaging in patients with congenital muscular dystrophy and Ullrich phenotype. *Neuromuscul Disord*. 2003;13(7-8):554-8. 395-397
35. Feng X, Luo S, Li J, Yue D, Xi J, Zhu W, et al. Fatty infiltration evaluation and selective pattern characterization of lower limbs in limb-girdle muscular dystrophy type 2A by muscle magnetic resonance imaging. *Muscle Nerve*. 2018;58(4):536-41. 398-400
36. Grande FD, Santini F, Herzka DA, Aro MR, Dean CW, Gold GE, et al. Fat-Suppression Techniques for 3-T MR Imaging of the Musculoskeletal System. *RadioGraphics*. 2014;34(1):217-33. 401-402
37. Dixon WT. Simple proton spectroscopic imaging. *Radiology*. 1984;153(1):189-94. 403
38. Hassler EM, Deutschmann H, Almer G, Renner W, Mangge H, Herrmann M, et al. Distribution of subcutaneous and intermuscular fatty tissue of the mid-thigh measured by MRI-A putative indicator of serum adiponectin level and individual factors of cardio-metabolic risk. *PLoS One*. 2021;16(11):e0259952. 404-407
39. Hassler E, Almer G, Reishofer G, Deutschmann H, Renner W, Herrmann M, et al. Investigation of the Relationship between the Mid\_Thigh Adipose Tissue Distribution Measured by MRI and Serum Osteocalcin—A Sex-Based Approach. *Nutrients*. 2022;14(1). 408-410
40. Müller W, Fürhapter-Rieger A, Ahammer H, Lohman TG, Meyer NL, Sardinha LB, et al. Relative Body Weight and Standardised Brightness-Mode Ultrasound Measurement of Subcutaneous Fat in Athletes: An International Multicentre Reliability Study, Under the Auspices of the IOC Medical Commission. *Sports Med*. 2020;50(3):597-614. 411-414
41. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods*. 2012;9(7):676-82. 415-416
42. Motiani KK, Collado MC, Eskelinen J-J, Virtanen KA, Löyttyniemi E, Salminen S, et al. Exercise Training Modulates Gut Microbiota Profile and Improves Endotoxemia. *Med Sci Sports Exerc*. 2020;52(1):94-104. 417-419
43. Codella R, Luzi L, Terruzzi I. Exercise has the guts: How physical activity may positively modulate gut microbiota in chronic and immune-based diseases. *Dig Liver Dis*. 2018;50(4):331-41. 420-421
44. Aragón-Vela J, Solis-Urra P, Ruiz-Ojeda FJ, Álvarez-Mercado AI, Olivares-Arancibia J, Plaza-Diaz J. Impact of Exercise on Gut Microbiota in Obesity. *Nutrients*. 2021;13(11). 422-423
45. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nature Reviews Microbiology*. 2021;19(1):55-71. 424-425
46. Castellanos N, Diez GG, Antúnez-Almagro C, Bressa C, Bailén M, González-Soltero R, et al. Key Bacteria in the Gut Microbiota Network for the Transition between Sedentary and Active Lifestyle. *Microorganisms*. 2020;8(5):785. 426-428
47. Chen H, Shen L, Liu Y, Ma X, Long L, Ma X, et al. Strength Exercise Confers Protection in Central Nervous System Autoimmunity by Altering the Gut Microbiota. *Front Immunol*. 2021;12:628629. 429-430
48. Castro AP, Silva KKS, Medeiros CSA, Alves F, Araujo RC, Almeida JA. Effects of 12 weeks of resistance training on rat gut microbiota composition. *J Exp Biol*. 2021;224(12). 431-432

49. Scheiman J, Luber JM, Chavkin TA, MacDonald T, Tung A, Pham L-D, et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. *Nature Medicine*. 2019;25(7):1104-9. 433  
434  
435
50. Bycura D, Santos AC, Shiffer A, Kyman S, Winfree K, Sutcliffe J, et al. Impact of Different Exercise Modalities on the Human Gut Microbiome. *Sports (Basel)*. 2021;9(2). 436  
437
51. Nay K, Jollet M, Goustard B, Baati N, Vernus B, Pontones M, et al. Gut bacteria are critical for optimal muscle function: a potential link with glucose homeostasis. *Am J Physiol Endocrinol Metab*. 2019;317(1):E158-e71. 438  
439  
440
52. Han JH, Kim IS, Jung SH, Lee SG, Son HY, Myung CS. The effects of propionate and valerate on insulin responsiveness for glucose uptake in 3T3-L1 adipocytes and C2C12 myotubes via G protein-coupled receptor 41. *PLoS One*. 2014;9(4):e95268. 441  
442  
443
53. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem*. 2003;278(13):11312-9. 444  
445  
446
54. Jakobsdottir G, Bjerregaard JH, Skovbjerg H, Nyman M. Fasting serum concentration of short-chain fatty acids in subjects with microscopic colitis and celiac disease: no difference compared with controls, but between genders. *Scand J Gastroenterol*. 2013;48(6):696-701. 447  
448  
449
55. Onrust L, Van Driessche K, Ducatelle R, Schwarzer K, Haesebrouck F, Van Immerseel F. Valeric acid glyceride esters in feed promote broiler performance and reduce the incidence of necrotic enteritis. *Poult Sci*. 2018;97(7):2303-11. 450  
451  
452
56. Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, et al. Drug treatment for spinal muscular atrophy types II and III. *Cochrane Database Syst Rev*. 2020;1(1):Cd006282. 453  
454  
455
57. Elshafay A, Hieu TH, Doheim MF, Kassem MAM, Eldoadoa MF, Holloway SK, et al. Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis. *CNS Drugs*. 2019;33(3):239-50. 456  
457  
458

459

460

461

**Figure legends:** 462

463

**Fig.1.** DIXON-MRI images of the mid-thigh. The cross-sectional muscle area was calculated from the water images (A) and the adipose tissue compartments were segmented from the fat images (B). 464  
465

466


**Fig. 2.a.** Scatterplot of the correlations between valeric acid (VA) and muscle area (MA) including regression line in males 467  
468

469

**Fig. 2.b** 470

Scatterplot of the correlations between valeric acid (VA) and muscle area (MA) including regression line in females. 471  
472

473



A

B




Figure 1



# Males: Valeric Acid versus MA




Figure 2a

## Females: Valeric Acid versus MA




Figure 2b